![William Skelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Skelly
Directeur/Membre du Conseil chez
ACURA PHARMACEUTICALS, INC.
Fortune : 676 $ au 30/04/2026
Profil
William G.
Skelly is Chairman, President & Chief Executive Officer at Central Biomedia, Inc. since 1990.
Mr. Skelly is Chairman, President & Chief Executive Officer at SERA, Inc. since 1990.
Mr. Skelly is Independent Director at Acura Pharmaceuticals, Inc. since 2000.
Mr. Skelly was President at Martec Pharmaceutical, Inc. from 1985 to 1990.
Mr. Skelly completed undergraduate studies at Michigan State University.
Mr. Skelly earned an MBA from the University of Missouri-Kansas City.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/01/2026 | 675 989 ( 1,02% ) | 676 $ | 30/04/2026 |
Postes actifs de William Skelly
| Sociétés | Poste | Début |
|---|---|---|
| ACURA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2000 |
SERA, Inc.
 SERA, Inc. Investment ManagersFinance Part of Central Biomedia, Inc., SERA, Inc. is a company that specializes in competitive immunotherapy products designed to prevent failure of passive transfer (FPT) in foals. The company is based in Shawnee Mission, KS. The company's flagship product, Seramune®, is an all-natural, concentrated equine serum administered orally shortly after birth to enhance passive immunity and reduce risks of infections such as gastrointestinal distress and pneumonia. Seramune® delivers approximately 30 grams of IgG per dose, is USDA licensed, sterile filtered, gamma irradiated, refrigerated (not frozen), and has a three-year shelf life. It is produced by pooling serum from multiple geldings without additives or preservatives and offers a higher IgG concentration compared to standard plasma products. SERA emphasizes cost-effective prophylactic immunotherapy to improve foaling outcomes and provides detailed product information, distributor networks, and technical guidance through its website. William G. Skelly has been the CEO of the company since 1990. | Directeur Général | 01/01/1990 |
Central Biomedia, Inc.
 Central Biomedia, Inc. BiotechnologyHealth Technology Manufactures private-labeled animal serum | Directeur Général | 01/01/1990 |
Anciens postes connus de William Skelly
| Sociétés | Poste | Fin |
|---|---|---|
Martec Pharmaceutical, Inc. | President | 01/01/1990 |
Formation de William Skelly
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
17
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Acura Pharmaceuticals, Inc.
 Acura Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical ingredients | Health Technology |
Michigan State University
 Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Central Biomedia, Inc.
Central Biomedia, Inc. BiotechnologyHealth Technology Manufactures private-labeled animal serum | Health Technology |
SERA, Inc.
SERA, Inc. Investment ManagersFinance Part of Central Biomedia, Inc., SERA, Inc. is a company that specializes in competitive immunotherapy products designed to prevent failure of passive transfer (FPT) in foals. The company is based in Shawnee Mission, KS. The company's flagship product, Seramune®, is an all-natural, concentrated equine serum administered orally shortly after birth to enhance passive immunity and reduce risks of infections such as gastrointestinal distress and pneumonia. Seramune® delivers approximately 30 grams of IgG per dose, is USDA licensed, sterile filtered, gamma irradiated, refrigerated (not frozen), and has a three-year shelf life. It is produced by pooling serum from multiple geldings without additives or preservatives and offers a higher IgG concentration compared to standard plasma products. SERA emphasizes cost-effective prophylactic immunotherapy to improve foaling outcomes and provides detailed product information, distributor networks, and technical guidance through its website. William G. Skelly has been the CEO of the company since 1990. | Finance |
Martec Pharmaceutical, Inc. | |
University of Missouri-Kansas City
 University of Missouri-Kansas City Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
